Mass Spec Meets Oncology

Premium

By William Langbein

 

Since the 1990s, monitoring biomarkers in the blood has been one of few noninvasive tools that an oncologist can use to diagnose cancer. Reliance on single biomarkers has been driven by a chemistry approach to research and wet lab technologies such as 2D gel electrophoresis — one antigen or protein can be isolated, characterized, and clinically linked to the presence of an invading tumor or cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more